Pfizer Inc (MIL:1PFE)
€ 24.62 -0.33 (-1.32%) Market Cap: 140.00 Bil Enterprise Value: 193.63 Bil PE Ratio: 34.77 PB Ratio: 1.58 GF Score: 59/100

Pfizer Inc at Truist Financial AI Symposium - Biotech & Tools Transcript

Mar 01, 2022 / 05:30PM GMT
Robyn Kay Shelton Karnauskas
Truist Securities, Inc., Research Division - Research Analyst

Hello, and good morning or good afternoon, everyone. My name is Robyn Karnauskas, one of the biotech analysts at Truist Securities. With me, I also have Kripa Devarakonda, also a biotech analyst. And I'd like to welcome you to our keynote presentation at our Truist Securities AI Symposium with Pfizer.

So the title of the talk is Pharma and AI -- is it the future? And this is a real-world case study of how it actually sped up development of the COVID vaccine.

So we'll start off with a presentation by Lidia Fonseca, Pfizer's Chief Digital and Technology Officer, followed by some Q&A. And with that, I will turn it over to Ronen and Lidia to begin the presentation.

Ronen Tamir
Pfizer Inc. - VP, Investor Relations

Thank you so much, Robyn. It is my obligation to make everybody aware of the fact that we're going to use some forward-looking statements in this presentation, among others about further digital strategy, our response to COVID-19, including

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot